{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:43:55Z","timestamp":1762868635245,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC0860700"],"award-info":[{"award-number":["2020YFC0860700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.intimp.2021.108112","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T11:11:56Z","timestamp":1631358716000},"page":"108112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies"],"prefix":"10.1016","volume":"100","author":[{"given":"Chunyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoqin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2021.108112_b0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"2","key":"10.1016\/j.intimp.2021.108112_b0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2021.108112_b0015","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic anti-tumor monoclonal antibodies","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.108112_b0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein & cell"},{"key":"10.1016\/j.intimp.2021.108112_b0025","first-page":"1260","volume":"343","author":"Diebolder","year":"2014","journal-title":"Complement is activated by IgG hexamers assembled at the cell surface"},{"key":"10.1016\/j.intimp.2021.108112_b0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.108112_b0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Lo Nigro","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.intimp.2021.108112_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2021.108112_b0045","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-15-1330","article-title":"Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer","volume":"75","author":"G\u00fcl","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.108112_b0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2021.108112_b0055","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2017.00280","article-title":"Fc\u03b3 Receptor Heterogeneity in Leukocyte Functional Responses","volume":"8","author":"Rosales","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108112_b0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.intimp.2021.108112_b0065","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1158\/0008-5472.CAN-17-2344","article-title":"slan(+) Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP","volume":"78","author":"Vermi","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.108112_b0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12334","article-title":"The many faces of Fc\u03b3RI: implications for therapeutic antibody function","volume":"268","author":"Swisher","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2021.108112_b0075","doi-asserted-by":"crossref","unstructured":"S. Herter, M.C. Birk, C. Klein, C. Gerdes, P. Umana, M. Bacac, Glycoengineering of therapeutic antibodies enhances monocyte\/macrophage-mediated phagocytosis and cytotoxicity, Journal of immunology (Baltimore, Md. : 1950) 192(5) (2014) 2252-60.","DOI":"10.4049\/jimmunol.1301249"},{"key":"10.1016\/j.intimp.2021.108112_b0080","doi-asserted-by":"crossref","unstructured":"M. Leidi, E. Gotti, L. Bologna, E. Miranda, M. Rimoldi, A. Sica, M. Roncalli, G.A. Palumbo, M. Introna, J. Golay, M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro, Journal of immunology (Baltimore, Md. : 1950) 182(7) (2009) 4415-22.","DOI":"10.4049\/jimmunol.0713732"},{"issue":"8","key":"10.1016\/j.intimp.2021.108112_b0085","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.intimp.2021.108112_b0090","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1172\/JCI115496","article-title":"Human Fc gamma RII, in the absence of other Fc gamma receptors, mediates a phagocytic signal","volume":"88","author":"Indik","year":"1991","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0095","first-page":"1454","article-title":"Fc\u03b3RIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk, Journal of B.U.ON. : official journal of the Balkan Union of","volume":"21","author":"Ziakas","year":"2016","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.intimp.2021.108112_b0100","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/eji.1830210820","article-title":"A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes","volume":"21","author":"Clark","year":"1991","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108112_b0105","first-page":"624","article-title":"Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes","volume":"83","author":"Bredius","year":"1994","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.intimp.2021.108112_b0110","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1086\/314920","article-title":"Fcgamma receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera","volume":"180","author":"Jansen","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2021.108112_b0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1128\/CVI.00037-09","article-title":"The Fcgamma receptor IIA-R\/R131 genotype is associated with severe sepsis in community-acquired pneumonia","volume":"16","author":"Endeman","year":"2009","journal-title":"Clin. Vaccine Immunol.: CVI"},{"issue":"1","key":"10.1016\/j.intimp.2021.108112_b0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-9343(01)01047-6","article-title":"Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease","volume":"112","author":"Domingo","year":"2002","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2021.108112_b0125","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40259-019-00381-2","article-title":"Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar","volume":"33","author":"Paek","year":"2019","journal-title":"BioDrugs : Clin. Immunother., Biopharm. Gene Ther."},{"issue":"8","key":"10.1016\/j.intimp.2021.108112_b0135","first-page":"1239","article-title":"Differential regulation of human monocytes and NK cells by antibody-opsonized tumors Cancer Immunology","volume":"67","author":"Yin","year":"2018","journal-title":"Immunotherapy : CII"},{"key":"10.1016\/j.intimp.2021.108112_b0140","doi-asserted-by":"crossref","first-page":"624661","DOI":"10.3389\/fonc.2020.624661","article-title":"Daratumumab for the Management of Newly Diagnosed and Relapsed\/Refractory Multiple Myeloma: Current and Emerging Treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2021.108112_b0145","doi-asserted-by":"crossref","first-page":"27150","DOI":"10.1038\/srep27150","article-title":"Enhancement of anti-STLV-1\/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody","volume":"6","author":"Sugata","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2021.108112_b0150","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108112_b0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Salles","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2021.108112_b0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.biologicals.2017.09.006","article-title":"Oxidation of M252 but not M428 in hu-IgG1 is responsible for decreased binding to and activation of hu-Fc\u03b3RIIa(His131)","volume":"50","author":"Cymer","year":"2017","journal-title":"Biol.: J. Int. Ass. Biol. Standard."},{"key":"10.1016\/j.intimp.2021.108112_b0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jbiotec.2020.04.017","article-title":"Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies","volume":"317","author":"Kuhns","year":"2020","journal-title":"J. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108112_b0170","doi-asserted-by":"crossref","first-page":"1803645","DOI":"10.1080\/19420862.2020.1803645","article-title":"Assessment of the role of afucosylated glycoforms on the in vitro antibody-dependent phagocytosis activity of an antibody to A\u03b2 aggregates","volume":"12","author":"Kwiatkowski","year":"2020","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.intimp.2021.108112_b0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1006145507567","article-title":"Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210","volume":"53","author":"Watanabe","year":"1999","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2021.108112_b0180","doi-asserted-by":"crossref","unstructured":"Y. Shi, X. Fan, H. Deng, R.J. Brezski, M. Rycyzyn, R.E. Jordan, W.R. Strohl, Q. Zou, N. Zhang, Z. An, Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fc\u03b3 receptors on macrophages, Journal of immunology (Baltimore, Md. : 1950) 194(9) (2015) 4379-86.","DOI":"10.4049\/jimmunol.1402891"},{"issue":"9","key":"10.1016\/j.intimp.2021.108112_b0185","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2011-06-364521","article-title":"Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function","volume":"119","author":"Tai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.108112_b0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2019.03.001","article-title":"A novel method for determining antibody-dependent cellular phagocytosis","volume":"468","author":"Kamen","year":"2019","journal-title":"J. Immunol. Methods"},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0195","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1080\/19420862.2019.1624123","article-title":"Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRP\u03b1","volume":"11","author":"Sim","year":"2019","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.intimp.2021.108112_b0200","doi-asserted-by":"crossref","first-page":"e95787","DOI":"10.1371\/journal.pone.0095787","article-title":"Development of a cell-based assay measuring the activation of Fc\u03b3RIIa for the characterization of therapeutic monoclonal antibodies","volume":"9","author":"Tada","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0205","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1189\/jlb.0804439","article-title":"The coordination of signaling during Fc receptor-mediated phagocytosis","volume":"76","author":"Swanson","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"18","key":"10.1016\/j.intimp.2021.108112_b0210","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.108112_b0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12974-015-0255-2","article-title":"Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition","volume":"12","author":"Rojanathammanee","year":"2015","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.intimp.2021.108112_b0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-811X-12-8","article-title":"Calcineurin\/NFAT signaling and innate host defence: a role for NOD1-mediated phagocytic functions","volume":"12","author":"Vandewalle","year":"2014","journal-title":"Cell Commun. Signal.: CCS"},{"key":"10.1016\/j.intimp.2021.108112_b0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2011.03.036","article-title":"Cyclophilin C-associated protein regulation of phagocytic functions via NFAT activation in macrophages","volume":"1397","author":"Yamaguchi","year":"2011","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.108112_b0230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2016.07.006","article-title":"Clarifying the Confusion between Cytokine and Fc Receptor \u201cCommon Gamma Chain\u201d","volume":"45","author":"Brandsma","year":"2016","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2021.108112_b0235","first-page":"6448","article-title":"Characterization and expression of the gene for the human Fc receptor gamma subunit","volume":"265","author":"K\u00fcster","year":"1990","journal-title":"Definition of a new gene family, J Biol Chem"},{"key":"10.1016\/j.intimp.2021.108112_b0240","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108112_b0245","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coi.2021.03.015","article-title":"The high affinity IgE receptor: a signaling update","volume":"72","author":"Blank","year":"2021","journal-title":"Curr. Opin. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2021.108112_b0250","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: a transcription factor comes of age","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0255","doi-asserted-by":"crossref","first-page":"e1007797","DOI":"10.1371\/journal.ppat.1007797","article-title":"NK cell-intrinsic Fc\u03b5RI\u03b3 limits CD8+ T-cell expansion and thereby turns an acute into a chronic viral infection","volume":"15","author":"Duhan","year":"2019","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.intimp.2021.108112_b0260","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1084\/jem.175.5.1381","article-title":"Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain","volume":"175","author":"Wirthmueller","year":"1992","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2021.108112_b0265","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/intimm\/4.11.1313","article-title":"Signaling function of reconstituted CD16: zeta: gamma receptor complex isoforms","volume":"4","author":"Vivier","year":"1992","journal-title":"Int. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2021.108112_b0270","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2005-09-3775","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes","volume":"107","author":"Cl\u00e9menceau","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2021.108112_b0275","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood.V86.9.3302.bloodjournal8693302","article-title":"Functional differences between two Fc receptor ITAM signaling motifs","volume":"86","author":"Van den Herik-Oudijk","year":"1995","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2021.108112_b0280","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2008-10-184457","article-title":"Differential signal transduction, membrane trafficking, and immune effector functions mediated by FcgammaRI versus FcgammaRIIa","volume":"114","author":"Dai","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.108112_b0285","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/mabs.2.1.10789","article-title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology","volume":"2","author":"Oflazoglu","year":"2010","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.intimp.2021.108112_b0290","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jbspin.2009.03.010","article-title":"Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects","volume":"76","author":"Renaudineau","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjh.15132","article-title":"New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies","volume":"180","author":"Meyer","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.intimp.2021.108112_b0300","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2021.108112_b0305","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/03639045.2017.1291672","article-title":"Design of experiments (DoE) in pharmaceutical development","volume":"43","author":"N. Politis","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"11","key":"10.1016\/j.intimp.2021.108112_b0310","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1359-6446(04)03086-7","article-title":"Application of statistical 'design of experiments' methods in drug discovery","volume":"9","author":"Tye","year":"2004","journal-title":"Drug Discov. Today"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921007487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921007487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:38:29Z","timestamp":1761586709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921007487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":62,"alternative-id":["S1567576921007487"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108112","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108112"}}